SYRE Spyre Therapeutics reports narrower Q4 2025 pershare loss than consensus forecasts with shares edging higher in todays trading Is DraftKings DKNG stock a market leader Q4 2025 EPS Tops Views Moderna Inc MRNA Counterparty Arbutus Biopharma Secures Regulatory Catalyst Amid Settled LNP Licensing Agreement